Methods and compositions for modulating apolipoprotein (a) expression
AssigneeIonis Pharmaceuticals, Inc.
InventorsRosanne M. Crooke, Mark J. Graham, Susan M. Freier, Marc Lim, Andrew Dibble
Life of this patent
Estimating the term…
Abstract
Disclosed herein are antisense compounds and methods for decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) or Lp(a). Certain diseases, disorders or conditions related to apo(a) or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The antisense compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.
Claims25
A method of treating, slowing the progression of, or ameliorating a symptom of hyperlipidemia in a subject, comprising:
- administering to said subject a compound comprising a modified oligonucleotide, wherein:
- the modified oligonucleotide consists of 14 to 25 linked nucleosides and comprises a nucleobase sequence comprising a portion of at least 14 contiguous nucleobases complementary to an equal length portion of nucleobases 3900 to 3923 of SEQ ID NO:
- 1, wherein the nucleobase sequence of the modified oligonucleotide is at least 95% complementary to SEQ ID NO:
- 1, including any salt thereof, whereby the administration treats, slows the progression of, or ameliorates a symptom of hyperlipidemia in the subject.
Dependencies are inferred from the claim text.